Zobrazeno 1 - 10
of 176
pro vyhledávání: '"Andrew Belch"'
Autor:
Meletios A. Dimopoulos, Jesus San-Miguel, Andrew Belch, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, James Morton, P. Joy Ho, Kihyun Kim, Naoki Takezako, Philippe Moreau, Jonathan L. Kaufman, Heather J. Sutherland, Marc Lalancette, Hila Magen, Shinsuke Iida, Jin Seok Kim, H. Miles Prince, Tara Cochrane, Albert Oriol, Nizar J. Bahlis, Ajai Chari, Lisa O’Rourke, Kaida Wu, Jordan M. Schecter, Tineke Casneuf, Christopher Chiu, David Soong, A. Kate Sasser, Nushmia Z. Khokhar, Hervé Avet-Loiseau, Saad Z. Usmani
Publikováno v:
Haematologica, Vol 103, Iss 12 (2018)
In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow up and include
Externí odkaz:
https://doaj.org/article/34bc86c721f547c0b175882c23aa9838
Autor:
Kevin W. Song, Meletios A. Dimopoulos, Katja C. Weisel, Philippe Moreau, Antonio Palumbo, Andrew Belch, Stephen Schey, Pieter Sonneveld, Lars Sternas, Xin Yu, Ramesh Amatya, Mara S. Monzini, Mohamed Zaki, Christian Jacques, Jesus San Miguel
Publikováno v:
Haematologica, Vol 100, Iss 2 (2015)
Externí odkaz:
https://doaj.org/article/cb8478be17484699830005e7d7c14ab5
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e33738 (2012)
Fatty acid synthase (FASN), a key player in the de novo synthetic pathway of long-chain fatty acids, has been shown to contribute to the tumorigenesis in various types of solid tumors. We here report that FASN is highly and consistently expressed in
Externí odkaz:
https://doaj.org/article/34016d09cef94804b4d98908f7fd97d2
Autor:
Eric J Bow, Joseph L Pater, Thomas J Louie, Ronald Feld, Lionel Mandell, Hugh G Robson, Anthony Chow, Andrew Belch, Lilly Miedzinski, Nancy Paul, Catherine R Elliott, Andrew R Willan
Publikováno v:
Canadian Journal of Infectious Diseases, Vol 3, Iss 5, Pp 235-239 (1992)
In the course of a multicentre clinical trial evaluating two antibacterial regimens for the empiric treatment of suspected infection in febrile neutropenic cancer patients, a suboptimal response was noted among recipients of antibacterial prophylaxis
Externí odkaz:
https://doaj.org/article/79c1b84df3de406b971be47aa471cc6c
Autor:
Meletios A Dimopoulos, Paul G Richardson, Nizar J Bahlis, Sebastian Grosicki, Michele Cavo, Meral Beksaç, Wojciech Legieć, Anna M Liberati, Hartmut Goldschmidt, Andrew Belch, Hila Magen, Alessandra Larocca, Jacob P Laubach, Maria T Petrucci, Donna Reece, Darrell White, María-Victoria Mateos, Ivan Špička, Mihaela Lazaroiu, Jesús Berdeja, Jonathan L Kaufman, Ying-Ming Jou, Alex Ganetsky, Mihaela Popa McKiver, Sagar Lonial, Katja Weisel, Irwindeep Sandhu, Monika Podhorecka, Antonio Palumbo, Adi Shacham-Abulafia, Iuliana Vaxman, Ofer Shpilberg, Britta Besemer, Maurizio Martelli, Roberto Foà, Paolo De Fabritiis, Tommaso Caravita di Toritto, Emanuil Gheorghita, Albert Oriol, Philip Rowlings, Angelucci Emanuele, Angelo M Carella, Massimo Offidani, Joan Bladé, Luis F Casado, Heather Oakervee, Victoria Panelli, Luis Meza, Thomas Kühr, Miguel Granell, Don Benson, Rajesh Nair, Viran Holden, James Reeves, Richard W Eek, Patricia A Walker, John Catalano, András Rosta, Ewa Lech-Marańda, Christy Samaras, Anthony Reiman, Robert Weaver, Peter Acs, Andrew Grigg, Bernard De Prijck, Martha Louzada, Leonard Minuk, Michael Sebag, Martine Klausmann, Manfred Welslau, Andrzej Hellmann, Catalin Danaila, Pamela Becker, William Bensinger, Bruce Porterfield, Manuel Modiano, Stephen M Schultz, Robert Manges, Huey-Shin Cindy Lee, James X Gray, Matthew P Wright, Marie-Christine Vekemans, Aryan Hamed, Zoltán Gasztonyi, Gábor Mikala, Tamás Masszi, Barbara Gamberi, Kazimierz Kuliczkowski, Lidia Usnarska-Zubkiewicz, Enrique Bengoechea, María AE Gutiérrez, Miguel TH García, Jesús San-Miguel, Christoph Driessen, Rajesh Behl, Warren Brenner, Carl Gray, Vincent Hansen, Mehdi Moezi, Hector V Cortes, Charles Yen, Laurent Gressot, Noemi Horvath, James M D'Rozario, Maya Latimer, Maria-Christine Kyrtsonis, Evgeni Chubar, Moshe Mittelman, Luca Baldini, Patrizia Tosi, Angelo Vacca, Wiesław W Jędrzejczak, Tadeusz Robak, Juan J Lahuerta, Jennifer Carney, Franklin Chen, Robert Hirsch, Marco Ruiz, Alvaro Alencar, Madan Jagasia, Samer Kasbari, Philip Kuriakose, Aftab Mahmood, Madhu Chaudhry, Gary Cohen, Stephen Noga, Sch Roa, Andrzej Jakubowiak, Cara Rosenbaum, Michel Delforge, Vanessa Delrieu, Chantal Doyen, Deeren Dries, Hilde Demuynck, Rik Schots, Vladimir Maisnar, Igor W Blau, Heinz A Dürk, Andrea Kerkhoff, Martin Kropff, Markus Munder, Christoph Röllig, Christof Scheid, Argiris S Symeonidis, Árpád Illés, Mark Coyne, Peter O'Gorman, Patrick Hayden, Michael O'Dwyer, Dina Ben-Yehuda, Andrei Braester, Anatoly Nemets, Gilles Lugassy, Yossi Cohen, Naomi Rahimi-Levene, Alberto Bosi, Sara Pezzatti, Fausto Rossini, Enrico M Pogliani, Antonello Pinto, Mieczysław Komarnicki, Gabriela Borsaru, Razvan Stoia, Boris Afanasyev, María A Goñi, Ana V Carboneras, Sarah Ali, S. Eric Rubenstein, Salvador Caputto, Thomas Cosgriff, Suzanne Fanning, Ali Khojasteh, Andrew Liman, Albert Malcolm, Nandagopal Vrindavanam, Ravindranath Patel, Rajesh Belani, Marie Shieh, Keith Stockerl-Goldstein, Charles Strnad, Robert Stuart, Saurabh Chhabra, Luciano Costa, Haresh Jhangiani, Bradley Augustson, Robin Filshie, Amanda Johnston, Mark S Hertzberg, Philippe Mineur, Susan Fox, Rami Kotb, Vi Dao, Richard LeBlanc, Evzen Gregora, Annamaria Brioli, Lars-Olof Mügge, Mathias Hänel, Christian Langer, Eleni Kapsali, Evangelos Briasoulis, Despoina Kyriakou, Izhar Hardan, Netanel A Horowitz, Cangialosi Clotilde, Francesco Fabbiano, Barbara Castagnari, Fabio Ciceri, Gerardo Musuraca, Andrzej Deptała, Janusz Kłoczko, Marius Balea, Ana-Maria Vladareanu, Victor Rossiev, Adrián Alegre, Cristina Encinas, Jorge Gayoso, Thomas Pabst, Neil Rabin, Sherri Arledge, Fernando Cabanillas, Joseph Catlett, Tarek Chidiac, David Clarkson, Madhav Dhodapkar, George Geils, Cyrus MA Khan, Entezam Sahovic, Mohamad Khasawneh, Rajesh Sehgal, Oscar Ballester, Moshe Levy, Joseph Fay, Kiem Liem, Matthew Lunning, Julie Vose, Edward Faber, Donald MacFarlane, Raymond Hohl, Tariq Mahmood, Birbal Bhaskar, Martha Mims, Ira Oliff, Agne Paner, John Maciejewski, Arvinda Padmanabhan, Robert Richard, Amit Sanyal, Gary Schiller, Harry Staszewski, Don Stevens, Christopher Vaughn, Kevin Windsor
Publikováno v:
The Lancet Haematology. 9:e403-e414
BACKGROUND: Elotuzumab plus lenalidomide and dexamethasone has shown improved progression-free and overall survival versus lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. We aimed to assess these regimens in p
Autor:
Nizar J. Bahlis, Thierry Facon, Matthew C. Cheung, Axel Tosikyan, Kevin W. Song, Andrew Belch, Christine Chen, Darrell White, Kenneth C. Anderson, Shankar Srinivasan, Suzanne Robinson, Angela Dispenzieri, Chaim Shustik, Diane Brown
Publikováno v:
Cancer Medicine
The phase 3 FIRST trial demonstrated significant improvement in progression‐free survival (PFS) and overall survival (OS) with an immune‐stimulatory agent, lenalidomide, in combination with low‐dose dexamethasone until disease progression (Rd c
Autor:
Bernardo Garichochea, Judit Demeter, Yuankai Shi, Umberto Vitolo, Enrica Morra, Margarida Marques, Miklos Egyed, Toshiki Uchida, Árpád Illés, Kenichi Ishizawa, Cristina Ligia Cebotaru, Ashis Mukhopadhyay, Masafumi Taniwaki, Sung-Soo Yoon, Cristina-Ligia Truica, Cheol Won Suh, Irina Lysenko, Naokuni Uike, Huaqing Wang, Achiel Van Hoof, Maryna Kyselyova, Osmanov Ea, Andrew Belch, Alexy Kuzmin, Caballero Gabarrón, Steven Van Steenweghen, Sergio Cancelado, Olga Samoilova, Kensei Tobinai, Kiyoshi Ando, Susumu Nakahara, Tatiana Scheider, Massimo Federico, Dmitry Udovitsa, Xiaoyan Ke, Yurii Lorie, Tatsu Shimoyama, Weerasak Nawarawong, Sebastian Grosicki, Gregor Verhoef, Nuriet Khuageva, Suporn Chuncharune, Fritz Offner, Albert Oriol Rocafiguera, Charles Farber, Ernst Späth-Schwalbe, Juliana Pereira, Ting Liu, Lee-Yung Shih, Steven Le Gouill, Miklos Udvardy, Richard Greil, Carmen Cao, Tomohiro Kinoshita, Horia Bumbea, Yasuhito Terui, Eva Gonzalez-Barca, Irina Bulavina, Peter Hu, Francisco Javier Capote, Olga Serduk, Akihiro Tomita, Ilseung Choi, Mahmut Gumus, Udomsak Bunworasate, Adriana Teixeira, Vladimir Merkulov, Yeow Tee Goh, Tadeusz Robak, Huiqiang Huang, Jie Jin, Cristina Ileana Burcoveanu, Halyna Pylypenko, Joaquín Díaz, Herlander Marques, Zoltán Gasztonyi, Vijay Rao Phooshkooru, Gayane Tumyan, Maike De Wit, Ali Khojasteh, Marcelo Capra, Vladimir Lima, Dai Maruyama, Viacheslav Pavlov, Georg Heß, Carmino Antonio De Souza, Zhao Wang, Iryna Kryachok, Amel Mezlini, Galvez Cardenas, Marina Golubeva, Lyudmila Kuzina, Patricia Santi, Remy Gressin, Balkis Meddeb, Xiaonan Hong, David Belada, Bernard De Prijck, Jan Maciej Zaucha, Jiri Mayer, Michinori Ogura, Rumiko Okamoto, Dolores, Irit Avivi, Mario Ojeda-Uribe, Grigoriy B Rekhtman, Jun Zhu, Reyes Arranz, Polina Kaplan, André Bosly, Ann Van De Velde, Kenny Mauricio, Yuri Dunaev, Anatoly Golenkov, Oleg Gladkov, Yoshiharu Maeda, Franco Cavalli, Dina Ben Yehuda, Michele Baccarani, Markus Raderer, Razvan Stoia, Carlos Appiani, Zvenyslava Masliak, Zita Borbenyi, Guiseppe Rossi, Julia Alexeeva, Johannes Drach, Kateryna Vilchevskaya, Georgii Manikhas, Jan Novák, Noppadol Siritanaratkul, Zhixiang Shen, Alexander Suvorov, Michael Crump, Pierre Zachee, Ofer Shpilberg, Sepideh Nemat, Mitsutoshi Kurosawa, Sreejith Nair, Bulent Undar, Govind Babu, Kudrat Abdulkadryrov, Adriana Sheliga
Publikováno v:
The Lancet Oncology. 19:1449-1458
Summary Background In the LYM-3002 study, the efficacy and safety of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were c
Autor:
Maria Roussou, Michel Delforge, Vania Hungria, G. Bries, Don Robinson, Anne-Marie Stoppa, Anna Potamianou, M. Spencer, Javier de la Rubia, Jesper Aagesen, Deniz Sargin, Evangelos Terpos, Lucia Ahlberg, Joris Diels, Cyrille Hulin, Meletios A. Dimopoulos, Andrew Belch, Robert Olie, Helgi van de Velde, Eirini Katodritou
Publikováno v:
European Journal of Haematology. 101:556-565
Objective The efficacy and safety of bortezomib-based therapy for relapsed/refractory multiple myeloma (RRMM) in clinical trials may differ from the oncology practice experience. The electronic VELCADE® OBservational Study was designed to prospectiv
Autor:
Jacob P. Laubach, Niels W.C.J. van de Donk, Tahamtan Ahmadi, Andrew Belch, Nizar J. Bahlis, Torben Plesner, Peter M. Voorhees, Clarissa M. Uhlar, Huaibao Feng, Paul G. Richardson, Sagar Lonial, Ming Qi, Jianping Wang, Brendan M. Weiss, Hareth Nahi, Saad Z. Usmani
Publikováno v:
Usmani, S Z, Nahi, H, Plesner, T, Weiss, B M, Bahlis, N J, Belch, A, Voorhees, P M, Laubach, J P, van de Donk, N W C J, Ahmadi, T, Uhlar, C M, Wang, J, Feng, H, Qi, M, Richardson, P G & Lonial, S 2020, ' Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma : final results from the phase 2 GEN501 and SIRIUS trials ', The Lancet Haematology, vol. 7, no. 6, pp. e447-e455 . https://doi.org/10.1016/S2352-3026(20)30081-8
The Lancet Haematology, 7(6), e447-e455. Lancet Publishing Group
The Lancet Haematology, 7(6), e447-e455. Lancet Publishing Group
Summary Background Daratumumab showed encouraging efficacy as monotherapy in patients with heavily pretreated multiple myeloma in the GEN501 and SIRIUS studies. Here we report a pooled, post-hoc final analysis of these two studies. Methods GEN501 was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ff9287699020810f638c78fcf43e906
https://research.vumc.nl/en/publications/2d5388d9-2ada-497b-a6e7-d98a23946662
https://research.vumc.nl/en/publications/2d5388d9-2ada-497b-a6e7-d98a23946662
Autor:
Anne Banos, Michel Attal, Salomon Manier, Christine Chen, Jin Lu, Javier de la Rubia, Andrew Belch, Michele Cavo, Angela Dispenzieri, Mourad Tiab, John Catalano, Guang Chen, Lugui Qiu, Aurore Perrot, Je-Jung Lee, Katja Weisel, Hervé Avet-Loiseau, Vanessa Houck, Philippe Moreau, Murielle Roussel, Thierry Facon, Nizar J. Bahlis, Heinz Ludwig, Kenneth C. Anderson, Antonello Pinto, Catarina Geraldes, Xavier Leleu, Bertrand Arnulf, Annette Ervin-Haynes, Albert Oriol, Lotfi Benboubker, Meletios A. Dimopoulos, Daniel Binder, Eileen M Boyle, Cyrille Hulin, Darrell White, Jamie D. Cavenagh, Michel Delforge, Mohamad Mohty
Publikováno v:
BLOOD
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
This FIRST trial final analysis examined survival outcomes in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) treated with lenalidomide and low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks